Q3 EPS Estimates for Shattuck Labs Raised by HC Wainwright

Shattuck Labs, Inc. (NASDAQ:STTK) – Equities research analysts at HC Wainwright upped their Q3 2026 earnings estimates for Shattuck Labs in a report released on Tuesday, August 11th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of ($0.09) for the quarter, up from their previous estimate of ($0.21). HC Wainwright has a “Buy” rating and a $14.00 price target on the stock. The consensus estimate for Shattuck Labs’ current full-year earnings is ($0.50) per share. HC Wainwright also issued estimates for Shattuck Labs’ Q4 2026 earnings at ($0.10) EPS, FY2026 earnings at ($0.42) EPS, FY2027 earnings at ($0.44) EPS and FY2028 earnings at ($0.52) EPS.

Several other equities research analysts also recently weighed in on the company. JPMorgan Chase & Co. began coverage on Shattuck Labs in a research report on Friday, July 24th. They issued an “overweight” rating and a $10.00 target price for the company. Wall Street Zen upgraded Shattuck Labs from a “hold” rating to a “buy” rating in a report on Saturday, June 13th. Needham & Company LLC increased their price objective on shares of Shattuck Labs from $14.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, June 8th. Jefferies Financial Group upgraded shares of Shattuck Labs to an “outperform” rating and set a $7.00 price objective on the stock in a research note on Friday, June 5th. Finally, Weiss Ratings raised shares of Shattuck Labs from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, June 16th. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Shattuck Labs presently has a consensus rating of “Moderate Buy” and a consensus target price of $12.12.

Shattuck Labs Trading Up 4.3%

Shares of Shattuck Labs stock opened at $7.49 on Thursday. Shattuck Labs has a twelve month low of $0.76 and a twelve month high of $8.33. The stock has a market cap of $574.33 million, a price-to-earnings ratio of -14.69 and a beta of 1.08. The company has a fifty day moving average price of $6.32 and a 200 day moving average price of $5.92.

Shattuck Labs (NASDAQ:STTK) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.12) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.12).

Hedge Funds Weigh In On Shattuck Labs

A number of hedge funds have recently bought and sold shares of STTK. Renaissance Technologies LLC lifted its holdings in Shattuck Labs by 77.4% during the 1st quarter. Renaissance Technologies LLC now owns 604,500 shares of the company’s stock worth $3,887,000 after buying an additional 263,800 shares during the last quarter. NEXTBio Capital Management LP acquired a new position in Shattuck Labs in the fourth quarter worth $11,497,000. Hsbc Holdings PLC acquired a new stake in shares of Shattuck Labs during the first quarter worth $269,000. Hillsdale Investment Management Inc. bought a new position in shares of Shattuck Labs in the 1st quarter worth about $421,000. Finally, S&G Foundation acquired a new position in shares of Shattuck Labs in the 2nd quarter valued at about $3,024,000. 58.74% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Arundathy N. Pandite sold 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $7.01, for a total transaction of $210,300.00. Following the completion of the sale, the insider owned 136,219 shares of the company’s stock, valued at approximately $954,895.19. This trade represents a 18.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Abhinav A. Shukla sold 23,365 shares of the firm’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $7.08, for a total transaction of $165,424.20. Following the sale, the insider directly owned 86,380 shares of the company’s stock, valued at $611,570.40. The trade was a 21.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 53,875 shares of company stock worth $379,305. 8.79% of the stock is currently owned by insiders.

Key Shattuck Labs News

Here are the key news stories impacting Shattuck Labs this week:

• Positive Sentiment: Positive Phase 1 data for SL-325: Shattuck reported a favorable safety profile, low immunogenicity, no evidence of DR3 agonism and durable blockade of TL1A binding. The results support the company’s view that SL-325 could potentially allow quarterly dosing and compete favorably in the inflammatory bowel disease market. Positive Phase 1 Data for SL-325
• Positive Sentiment: Phase 2b trial approaching: The RECEPTIVE-CD1 study of SL-325 in approximately 232 Crohn’s disease patients is expected to begin in the third quarter of 2026. The primary efficacy data are expected in the first half of 2028, creating a major future catalyst if the trial demonstrates clinical benefit. SL-325 Crohn’s Trial Update
• Positive Sentiment: Extended cash runway: Cash, cash equivalents and short-term investments totaled approximately $208.3 million at June 30, 2026, helped by an $86.2 million public offering and $57.1 million from exercised warrants. Management expects current resources to fund operations into 2029, reducing near-term financing risk.
• Positive Sentiment: Pipeline expansion: Shattuck introduced SL-846, a DR3 x IL-23 receptor bispecific antibody, with initial Phase 1 data expected in 2027. This adds another potential growth opportunity beyond SL-325.
• Neutral Sentiment: Earnings met expectations: Second-quarter EPS was a loss of $0.12, matching consensus. However, the company generated no revenue and remains dependent on clinical development and capital markets.
• Neutral Sentiment: Analyst outlook remains constructive: HC Wainwright lowered its price target from $18 to $14 but maintained a Buy rating. Analysts overall have issued a Moderate Buy consensus, with targets substantially above the current trading level. Consensus Analyst Rating
• Negative Sentiment: Higher operating losses: Second-quarter net loss increased to $15.2 million from $12.5 million a year earlier, while R&D spending rose to $11.7 million. The company’s valuation therefore continues to depend heavily on successful future trial results.

About Shattuck Labs

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.